Covagen covagen.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fyno...Show all

Company (Acquired)

Phone: +41(0)44 732 46 60

Fax:

Wagistrasse 25

Zurich, CH-8952
Switzerland

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Covagen $72.6M Aug 25, 2014
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Covagen Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Competitors

Company Status Description Investors

BioMimetic Therapeutics

Franklin, Tennessee, United States
AcquiredBioMimetic Pharmaceuticals (BMTI) is a biopharmaceutical company focused on the development, commercialization and ultimate marketing of protein therapeutics for tissue and organ regeneration. The Company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB). In March 2013, BioMimetic Therapeutics was acquired by Wright Medical Group. The valuation of BioMimetic Therapeuti...Show allLogin to see details

Xencor

Monrovia, California, United States
IPO / Went publicXencor engineers biotherapeutics using its Protein Design Automation technology platform, and is a provider in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb antibody drug candidates in the clinic, including XmAb5871 targeting CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb2513 for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of biosu...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Human serum albumin binding compounds and fusion proteins thereof Dec 18, 2013 Oct 17, 2017 Patent
Binding molecules with antitumoral activity Mar 08, 2013 Mar 14, 2017 Patent
Il-17 binding compounds and medical uses thereof Aug 24, 2010 Jun 28, 2016 Patent
Il-17a binding molecules and medical uses thereof Sep 19, 2013 Apr 19, 2016 Patent
Chymase binding compounds and medical uses thereof Apr 24, 2012 Jul 21, 2015 Patent
See all 7 patents